SNDX.O (SNDX.O) News
Follow SNDX.O (SNDX.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Oct 12 (Reuters) — Syndax Pharmaceuticals, Inc.: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis Syndax Pharmaceuticals - Will Not Pursue Further Development Of
NEWS | Oct 12, 2026, 09:30 PM UTC
L
Syndax says mid — stage trial of lung disease treatment fails main goal, ends development
Oct 12 (Reuters) — Syndax Pharmaceuticals said on Monday it will stop developing a treatment for idiopathic pulmonary fibrosis, a chronic lung-scarring disease, after a mid-stage trial failed to meet its main goal. Share
CENTRAL_BANK | Oct 12, 2026, 08:40 PM UTC
L
Syndax axatilimab misses primary endpoint in Phase 2 IPF trial, drops further development in indication
Syndax reported topline results from its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis. The study missed its primary goal, leading Syndax to drop further development of axatilimab in idiopathic pul
NEWS | Oct 12, 2026, 08:02 PM UTC